This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price.
Shanyue Zeng, MA
Advertisement
Shanyue Zeng, MA, is a data scientist at IQVIA Market Access Technology Solutions.
ORCID ID: 0009-0008-0593-0473
Articles by Shanyue Zeng, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5
